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Abstract
Previous proteomic studies have identified alpha 1-antitrypsin (A1AT) as a potential serum biomarker for colorectal cancer
(CRC). In this case-control study, we evaluated plasma A1ATconcentration and activity as a biomarker for the early diagnosis of
colorectal cancer in a group of 113 sporadic CRC patients. We also analyzed A1AT gene promoter methylation, and genotypes in
this group of CRC patients. The plasma A1AT and CEA concentrations were measured using the nephelometric and ELISA
methods, respectively. A1AT activity was determined by Trypsin Inhibitor Capacity assay. The genomic DNA from blood
samples were subjected to Z and S genotype analysis using PCR-RFLP method and the gene promoter methylation in tumors
and their adjacent normal tissues was determined by methylation specific-PCR assay. The plasma levels of A1AT and CEA in
patients (median, 2.3 g/L and 5.96 ng/ml, respectively) were significantly higher than those in healthy controls (medians, 1.43 g/L
and 2.57 ng/ml, respectively) (p = 0.0001). The plasma A1AT activity and concentrations were positively correlated with the
tumor stage and well-discriminated between early and advanced stages. The A1ATactivity in plasma was the most useful marker
for CRC diagnosis (median 4.8 mmol/min/ml in cases vs 1.91 mmol/min/ml in controls, p = 0.0001). No deficient Z or S alleles
of A1ATwas observed in patients’ genotype and the gene promoter tends to be more methylated in normal mucosa than in tumor
tissues. We conclude that plasma A1AT activity has better sensitivity and specificity than CEA measurement for the early
detection of CRC. Promoter demethylation might play a role in increasing plasma A1AT levels in CRC patients.
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Background
Colorectal cancer (CRC) is one of the leading causes of cancer-
related mortality worldwide [1] and its incidence in Iran has
also dramatically increased during the last few decades [2].
Serum-based sensitive biomarker for the early detection of
CRC is essential for effective treatments and disease-free
survival of patients. Measurement of carcinoembryonic antigen
(CEA) level in the serum of CRC patients is widely used for
monitoring disease progression and recurrence after treatment
[3]. It has been suggested that the preoperative serum CEA
level might be also a useful indicator for CRC-liver metastasis
[4, 5]. However, CEA lack sufficient specificity and sensitivity
to be considered for specific diagnosis or early malignancy
detection [6]. Therefore, the identification of new non-
invasive serum-based biomarkers for the accurate detection of
the early stage CRC is an open field of research.
Previous studies have suggested associations between in-
flammatory process and development of several types of can-
cer [7, 8]. The association between chronic inflammation and
CRC risk is controversial. Some studies have reported positive
associations between serum inflammatorymarkers, C-reactive
protein (CRP) and haptoglobin and CRC risk [9, 10]. Alpha-
1-antitrypsin (A1AT), a major serum serine proteinase inhib-
itor, is highly expressed during inflammation predominantly
by liver hepatocytes. In addition to liver hepatocytes, A1AT
gene is also expressed in human blood monocytes and
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intestinal epithelium, and colonic tumor cell lines [11]. A1AT
as an acute phase protein, primarily protects the connective
tissue of lungs against serine proteases including neutrophil
elastase [12]. A1AT also demonstrates anti-inflammatory ac-
tivity by inhibiting inflammatory responses and cytokine pro-
duction by phagocytic cells, such as macrophages, mono-
cytes, and neutrophils [13, 14].
Several clinical studies have indicated increased serum
A1AT levels in various types of malignancy, such as lung,
liver, bladder, breast, prostate, pancreas, and esophageal can-
cer [15–19]. A1AT has been also suggested as a potential
diagnostic biomarker for the early-stage detection of gastroin-
testinal inflammation [20]. The relationship between serum
A1AT levels and CRC remains controversial. Few studies to
date have investigated the association between A1AT activity
and the risk of CRC [21–24]. Both high and low concentra-
tions of serum A1AT levels have been proposed to be associ-
ated with CRC incidence [22, 23, 25, 26]. A positive correla-
tion between serum levels of A1AT and the clinical stage of
CRC progression has been also reported [21, 22, 26]. Several
polymorphisms of the A1AT gene (SERPINA1) are associated
with the low level of plasma A1AT protein and the most com-
mon deficiency-associated A1AT genotypes are protease in-
hibitor Z (PiZ) and protease inhibitor S (PiS) variants [27].
Deficient Z and S alleles of A1AT have been reported to be
associated with an increased risk for developing certain can-
cers including hepatocellular carcinoma, lung, and bladder
cancer [16, 17, 28].
DNA methylation is a major epigenetic mechanism in-
volved in the regulation of gene transcription. Previous studies
have suggested that the promoter DNA methylation might
play a role in the regulation of A1AT gene expression [29,
30]. The present case-control study was performed to investi-
gate the association between A1AT activity, A1AT genotype
variation, A1AT gene promoter methylation, and CRC sus-
ceptibility in patients from Fars, a southern province of Iran.
The diagnostic value of preoperative serum A1AT was also
assessed and compared with CEA, the most widely used
marker in CRC patients.
Methods
Blood and Tissue Samples
A total of 113 preoperative blood samples and 86 surgical
resected CRC tumor tissues were obtained from the
university-affiliated Shahid Faghihi hospital in Shiraz,
Southern Iran. Tumor samples were snap frozen immediately
after surgical resection and stored at −80 °C.
Blood samples were also collected from 50 age and sex-
matched healthy blood donors having no history of cancerous
or genetic diseases as control subjects. Blood and plasma
samples were stored at −80 °C until analysis. The study pro-
tocol was approved by the university ethical committee
(Approval Number: 92–15,865/ 03-08-2013) and signed in-
formed consent was obtained from study subjects.
Measurement of Plasma A1AT Concentration, A1AT
Activity and CEA Levels
The plasma A1AT level was measured by nephelometry using
commercially available antibodies (MININEPH, Birmingham,
UK), with an Array™ Protein System autoanalyzer (Beckman
Instruments, Brea, California, USA). A1AT activity was deter-
mined by Trypsin Inhibitor Capacity (TIC) assay using the
chromogenic substrate α-N-benzoyl DL-argenine-p-
nitroanilide (BAPNA, Sigma) as described previously [31].
The concentration of CEA in plasma samples was determined
using a commercial CEA EIA kit (CanAg, Sweden), with a
microplate reader (Mikura Optica LTD, UK) following the
manufacturer’s instructions.
DNA Extraction and Genotyping
Genomic DNAwas extracted from peripheral blood leucocytes
and tissue samples using the standard phenol-chloroform proto-
col. Two single nucleotide polymorphisms (SNPs) of serpinA1
gene, S variant (rs17580) and Z variant (rs28929474), associated
with A1AT deficiencies were genotyped by PCR followed by
restriction fragment length polymorphism (RFLP) analysis.
Briefly, PCR reaction was carried out in a 50 μL reaction mix-
ture containing 0.1 mM dNTPs, 1.5 mMMgCl2, 10 pM of each
specific oligonucleotide primers (Table 1), 150 ng of genomic
DNA, and 0.25 U of Taq DNA polymerase (MBI Fermentas,
Vilnius, Lithuania). Amplification was carried out with an initial
denaturation at 94 °C for 5 min, and then 35 cycles of 94 °C
denaturation, 57 °C annealing, and 72 °C extension, each for
45 s, followed by a final extension at 72 °C for 10min, in a PCR
thermal cycler (Eppendorf, Germany). For RFLP analysis, 10 μl
of PCR products were digested with 10 U Taq I restriction
enzyme (MBI Fermentas, Vilnius, Lithuania) at 65 °C for 2 h,
and digestion products were analyzed on 2% (w/v) agarose gel.
Bisulfite Treatment of DNA and Methylation-Specific
PCR (MS-PCR)
The status of promoter methylation of SERPINA1 gene in
tumors and their adjacent normal tissues was determined by
MS-PCR. Bisulfite modification of each DNA sample was
performed as previously described [32] and bisulfite-treated
DNAwas PCR-amplified using primers (Table 1) designed for
specific amplification of both methylated and unmethylated
promoter region of the gene. Amplification was performed
by an initial denaturation at 95 °C for 5min, and then 40 cycles
of denaturation at 95 °C for 45 s, primer annealing at 60 °C for
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30 s, extension at 72 °C for 30 s, followed by a final extension
at 72 °C for 10 min. In every sodium bisulfite modification
reaction, DNA from human liver HepG2 cell line and human
methylated DNA standard (ZYMO Research, Freiburg,
Germany) were used as unmethylated (negative) and methyl-
ated (positive) controls, respectively. MS-PCR reaction prod-
ucts were separated by electrophoresis on 2% agarose gel.
Statistical Analysis
Statistical analyses were performed using SPSS Software ver-
sion 17 (SPSS, Inc., Chicago), MedCalc version 14 (MedCalc
Software, Ostend, Belgium), and GraphPad Prism version 5
(GraphPad Software Inc., San Diego, CA, USA). Quantitative
variables are expressed as medians or means and standard
error of mean (mean ± SEM). Parameters were compared be-
tween cancer cases and healthy controls by using the Student’s
t test. One-way analysis of variance ANOVA and multiple
comparisons (post-hoc) pairwise Tukey’s test were applied
to evaluate the differences of some markers according to the
stage and grade of tumors. Correlation coefficient (r) was cal-
culated by Pearson or Spearman correlation test. Area under
receiver operating characteristic (ROC) curve was used to
compare serum markers diagnostic accuracy and to verify
whether they could be used to discriminate between CRC
cases and controls. Associations between methylation and
clinical, biological features of tumors were evaluated using
Chi square or Fisher’s exact test, as appropriate. A p value
of ≤0.05 was considered to be statistically significant.
Results
The study group consisted of 113 patients including 59
(52.2%) males with an average age of 60.98 ± 2.05 years
and 54 (47.8%) females with an average age of 54.35 ±
1.8 years. The control group consisted of 50 healthy individ-
uals including 28 (56%) of males with an average age of
59.03 ± 1.47 years and 22 (44%) of females with an average
age of 61.04 ± 2.01 years. Ninety-six patients (85%) had tu-
mors in the left side of colon, 5 patients (4.42%) had malig-
nancies in the right side colon, and 9 (8%) had total colectomy.
In this group of patients, 72 (63.7%) of tumors were well-
differentiated, 25 (22.1%) were moderately differentiated, 4
(3.5%) were poorly differentiated, and 3 (2.7%) were mucin-
ous. The tumors were classified as stage I in 31 (27.4%), stage
II in 36 (31.9%), stage III in 26 (23.0%), and stage IV in 8
(7.1%) of patients (Table 2).
Measurement of A1AT Activity and Concentrations
of CEA and A1AT in Plasma
Analysis of plasma data revealed significant differences be-
tween cases and controls in the levels of CEA and A1AT
concentrations as well as plasma A1AT activity (Table 2).
The range of CEA concentrations were 0.42–164.25 ng/ml
(median 5.96 ng/ml) in the patients with CRC compared to
0.26–10.8 ng/ml (median 2.57 ng/ml) in the healthy controls
(p < 0.0001). The range of A1AT levels in plasma was 1.05–
4.24 g/L (median 2.3 g/L) in patients and 1.01–2.13 g/L (me-
dian 1.43 g/L) in controls (p = 0.0001). The range of plasma
A1AT activity from cancer patients and control group were
1.36–7.82 μmol/ min /ml (median 4.8) and 1.15–2.91μmol/
min /ml (median 1.91), respectively (p = 0.0001). Age and
gender-stratified analyses reveled that all sex and age (<60
and ≥ 60) subgroups of patients had higher CEA and A1AT
values than their respective controls (Table 2). There were,
however, no significant differences in the mean values of
plasma A1AT activity and CEA and A1AT concentrations in
either cases or controls stratified by sex or age.
Relationship Between Plasma Biomarkers
and Clinicopathological Features of CRC Patients
The correlation of mean values of the parameters measured in
patient’s sera to the clinicopathological features of the disease
Table 1 Primers’ sequence and
the annealing temperature used
for A1AT genotyping and MS-
PCR
Sequence Product size (bp)
Genotyping
S allele F: 5’-TGAGGGGAAACTACAGCACCT −3′
R: 5’-AGGTGTGGGCAGCTTCTTGGTCA-3’
121
Z allele F: 5’-ATAAGGCTGTGCTGACCATCGTC-3′
R: 5′-TTGGGTGGGATT CACCACTTTTC-3’
179
MS-PCR
SERPINA1 (U) F: 5′-TAGGTAAAGTGTTTGGGTAGTG-3′
R: 5′-AACAAAACCCTATCCTCATCCA-3′
171
SERPINA1 (M) F: 5′-AGGTAAAGCGTTCGGGTAGCG-3′
R: 5′-ACAAAACCCTATCCTCGTCCG-3′
169
F Forward, R Reverse, U Unmethylated, M Methylated
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are shown in Table 2. There were no significant differences in
the mean plasma CEA or A1AT concentrations and A1AT
activity levels between patient groups divided based on tumor
site (Table 2). In our study group, 70 patients (68.6%) had
tumors smaller than 5 cm and 32 patients (31.4%) had tumors
larger than 5 cm.
The statistical analysis indicated that the mean value of
A1AT concentration and A1AT activity levels were signifi-
cantly higher in plasma of patients with large tumor size
(≥5 cm) than those with small tumors (<5 cm) (P < 0.05)
(Table 2). The range of A1AT concentrations in CRC patients
with large tumor size and small tumor size were 1.25–4.24
(median 2.73) g/L and 1.05–3.55 (median 2.15) g/L (p =
0.0001), respectively. The range of plasma A1AT activity
levels in patients with large tumor size was 1.91–7.82 (median
5.26) and in patients with small tumor was1.36–7.63 (median
4.5) μmol/ min /ml (p = 0.01). There was no significant differ-
ence in the mean of plasmaCEA concentration between tumor
size subgroups.
The range of plasma CEA in stage I, II, III, and IV were
1.33–138.89 (median 5.1), 0.42–116.94 (median 5.67), 0.5–
31.72 (median 7.72), and 1.23–164.25 (median 39.35) ng/ml,
respectively. The CEA level in CRC patients at stage IV was
significantly higher than those in other stages and in the control
group (P = 0.0001) (Fig. 1a). As shown in Fig. 1b, the mean of
plasma CEA levels in patients with poorly differentiated tumor
was significantly higher than those in with well andmoderately
differentiated tumor (P < 0.05). There were no significant dif-
ferences in the mean A1AT concentration and A1AT activity
levels between various differentiation groups. The mean serum
levels of plasma A1AT activity and concentration in all stages
of colorectal cancer were significantly higher than in healthy
controls (Fig. 1c and d). In patients with stage I tumors the
mean values of plasma A1AT concentrations and activity was
significantly lower than in the remaining subgroups (P < 0.05).
The range of A1AT concentrations determined in patients with
tumor stage I, II, III, and IV were 1.05–3.55 (median 1.58),
1.22–4.24 (median 2.28), 1.15–3.48 (median 2.67), and 1.68–
3.5 (median 2.96) g/L, respectively. The range of A1AT activ-
ity in stage I, II, III and IV were 1.40–7.30 (median 2.85),
1.36–7.82 (median 4.66), 2.77–7.43 (median 5.44), and 3–
7.30 (median 5.99) μmol/ min /ml, respectively.
In CRC patients, A1AT concentration was positively cor-
related with CEA concentration (r = 0.2, p = 0.03), but there
was no significant correlation between plasma A1AT activity
and CEA level (r = 0.112, p = 0.23). The area under the ROC
curve (AUC) of A1AT concentration and activity were signif-
icantly higher than AUC of CEA (P = 0.01, P < 0.0001,
Table 2 Plasma A1AT and CEA concentration and A1AT activity level according to some clinical features of cases and controls
Group A1AT
median
(g/L)
A1AT
Mean ± SEM
(g/L)
aP bP A1AT activity
Median
(μmol/min/ml)
A1AT activity
Mean ± SEM
(μmol/min/ml)
aP bP CEA
Median
(ng/ml)
CEA
Mean ± SEM
(ng/ml)
aP bP
Case (n)
Total (113) 2.3 2.34 ± 0.06 0.0001 4.8 4.77 ± 0.15 0.0001 5.96 15.39 ± 2.7 0.0001
Age
<60 (62) 2.36 2.4 ± 0.09 0.0001 NS 4.86 4.83 ± 0.21 0.0001 NS 5.7 17.58 ± 4.2 0.001 NS
≥60 (48) 2.23 2.2 ± 0.09 0.0001 4.75 4.62 ± 0.21 0.0001 6.5 13.38 ± 3.66 0.007
Sex
Female (54) 2.4 2.36 ± 0.09 0.0001 NS 4.6 4.6 ± 0.24 0.0001 NS 5.8 15.29 ± 4.21 0.009 NS
Male (59) 2.26 2.32 ± 0.08 0.0001 5.07 4.8 ± 0.18 0.0001 6.01 15.48 ± 3.7 0.001
Tumor size
<5 cm (70) 2.15 2.1 ± 0.07 0.0001 4.51 4.4 ± 0.19 0.01 5.88 11.77 ± 2.48 NS
≥5 cm (32) 2.73 2.6 ± 0.12 5.26 5.2 ± 0.26 7.27 18.88 ± 6.14
Missing (11)
Tumor site
Right side (5) 2.56 2.4 ± 0.34 NS 3.63 4.96 ± 0.82 NS 3.38 31.03 ± 22.22 NS
Left side (96) 2.31 2.3 ± 0.06 4.78 4.77 ± 0.16 6.57 13.61 ± 2.54
Total Colectomy (9) 2.45 2.48 ± 0.25 4.8 4.49 ± 0.65 2.3 30.02 ± 18.77
Missing (3)
Control (n)
Total (50) 1.43 1.4 ± 0.03 1.91 2 ± 0.05 2.57 3.22 ± 0.36
Age
<60 (30) 1.48 1.5 ± 0.04 NS 1.93 2.02 ± 0.08 NS 2.64 3.4 ± 0.5 NS
≥60 (20) 1.4 1.48 ± 0.06 1.87 1.98 ± 0.08 2.16 2.8 ± 0.51
Sex
Female (22) 1.4 1.48 ± 0.05 NS 1.84 1.94 ± 0.09 NS 2.9 3.7 ± 0.61 NS
Male (28) 1.43 1.50 ± 0.05 1.93 2.05 ± 0.07 2.55 2.8 ± 0.42
NS Not significant
aP-values for case–control comparisons from the Student’s t test where appropriate
bP-values for subgroups comparison from the Student’s t test where appropriate
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respectively) (Fig. 2a). The AUC of plasmaA1ATactivity was
also significantly more than the AUC of A1AT concentration
(P = 0.0004). The AUC for CEA and A1AT concentrations
and A1AT activity were 0.74 (95% CI: 0.67–0.81), 0.86
(95% CI: 0.80–0.91), and 0.94 (95% CI: 0.89–0.97), respec-
tively. At a cut-off point of 3.56 ng/ml for CEA, the optimal
sensitivity and specificity were 70.8% and 70%, respectively
for discriminating CRC patients from healthy controls (Fig.
2b). The ideal cut off value identified from the ROC curve for
A1AT concentration was 1.88 mg/L with the sensitivity of
75.2% and the specificity of 90% in detecting cancer patients
from healthy controls (Fig. 2c). The ideal cut-off value for
plasma A1AT activity was 2.91 μmol/ min /ml with the sensi-
tivity of 84.1% and the specificity of 100% for discriminating
cancer patients from healthy controls (Fig. 2d).
SERPINA1 Genotype and Promoter DNA Methylation
DNA samples from CRC patients were analyzed for Z or S
alleles in SERPINA1 gene by PCR-RFLP method, as de-
scribed in the BMethods^ section. Taq I digestion of the
PCR-amplified product using either Z or S primers results in
two fragments for the normalM allele. The presence of mutant
Z or S allele abolishes the Taq I restriction site within the
amplified fragments. Agarose gel electrophoresis of PCR-
RFLP products (Fig. 3a and b) produced no detectable S or
Z mutation in all 113 samples studied. The results indicated
that normal homozygous MM genotype of SERPINA1 gene is
present in this group of CRC patients.
We also investigated the promoter methylation status of
SERPINA1 gene in CRC tumors and their adjacent normal
tissues in a subgroup of 86 patients. Illustrative examples of
MS-PCR results of the promoter methylation analysis are
shown in Fig. 3c. Table 3 summarizes the association between
SERPINA1 promoter methylation and clinicopathological
characteristics of CRC patients. SERPINA1 promoter was ful-
ly methylated in 7 (8.1%) and partially methylated
(hemimethylated) in 79 (91.9%) of tumors. The frequency of
fully methylated SERPINA1 promoter in normal colorectal
mucosa was significantly higher than that in tumor tissues
(53.2% versus 8.1%, p < 0.0001). There was also significant
association between differentiation state of tumors and
SERPINA1 gene methylation. Six out of 7 tumors (85.7%)
with fully-methylated SERPINA1 gene were well-
differentiated (p = 0.02). There was no significant association
between SERPINA1 gene methyla t ion and other
clinicalpathological features of CRC patients (Table 3).
Discussion
The relationship between A1AT and CRC has been controver-
sial, both higher and lower blood levels have been reported as
compared to healthy controls [20, 22, 26]. The results of
Fig. 1 Plasma CEA (a) and
A1AT concentration (b) and
A1AT activity (c) in the healthy
controls and CRC patients
according to tumor stages. P
value from Tukey test.
*significant difference (p =
0.0001)
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present study corroborate previously published studies show-
ing a significantly higher concentration of serum A1AT in
CRC patients than in healthy controls [22, 26]. The mean plas-
ma values of A1AT and CEA concentrations and A1AT activ-
ity in CRC patients were significantly higher than those of the
healthy blood donors (p = 0.0001, Table 2). Moreover, our
results suggest a better sensitivity of plasma A1AT than CEA
for early detection of CRC. A detailed analysis revealed that
the concentration and activity of A1AT in plasma progressively
increased with increasing severity of the colorectal cancer.
Moreover, the mean A1AT concentration and activity in pa-
tients with all stages and grades of tumors were also higher
than those in controls (p < 0.01) (Fig. 1). But only patients with
stage IV of CRC had significantly higher plasma CEA than
normal controls and the mean CEA levels only in the subgroup
of patients with poorly differentiated tumors was significantly
different from other differentiation subgroups (Fig. 1b). In
agreement with a previous report [22], we also observed a
higher serum A1AT concentrations in cases with high stage
(III and IV) than those with early stage tumors (I and II).
CEA is the most widely used tumor marker especially for
monitoring CRC treatment. But, because of lack of sufficient
sensitivity and specificity it could not be used for screening or
Fig. 2 The sensitivity and
specificity analysis of plasma
A1AT and CEA for detection of
CRC. a ROC curves comparing
A1AT and CEA concentration
and A1AT activity in plasma of
CRC patients. The area under
ROC curves for A1AT activity
and concentration and CEA level
were 0.94, 0.74, and 0.86,
respectively. b, c, and d indicate
the cut-off value with the highest
accuracy (minimal false negative
and false positive) for each
marker
Fig. 3 Genotype and promoter DNA methylation analysis of Serpin A1
gene in CRC patients. a PCR-RFLP assay for the detection of Z mutation
of A1AT gene in DNA isolated from patients’ blood. Taq I enzyme
digestion of the 179-bp PCR amplified M allele yields two fragments of
157 and 22 bp (lanes 1–10), whereas the Z allele results in an undigested
fragment. Lane C (control) is a 179-bP undigested PCR product. b PCR-
RFLP assay for the detection of S allele. Taq I digestion of the 121-bp
PCR-amplified M allele yields two fragments of 100 and 21 bp (lanes 1–
10), whereas the S allele results in an undigested fragment. Lane C
(control) is a 121-bp undigested PCR product. c Representative examples
of MS-PCR reactions for promoter methylation analysis of Serpin A1
gene in primary CRC tumors. U: Unmethylated gene; M: Methylated
gene; C (+): Methylated control; C (−): Umethylated control; MR:
50 bp DNA size marke
H. Jaberie et al.1170
diagnosis. The ROC curve analysis indicated that plasma
A1AT has a better sensitivity and specificity than CEA to
discriminate CRC patients from healthy individuals. While
at the optimal cut off value, plasma CEA levels had a sensi-
tivity of 70.8% and specificity of 70% for discriminating CRC
cases from controls, A1AT in plasma had a sensitivity and
specificity of 75.2% and 90%, respectively (Fig. 2). Nine per-
cent of CRC cases were cigarette smokers. Since smoking has
been reported to increase blood CEA level, we evaluated the
possible effect of smoking on the plasma CEA levels. The
difference in plasma CEA concentrations between smokers
and non-smokers was not statically significant (data not
shown) (p > 0.05).
At the optimal cut off, the predicted probability on the
basis of plasma A1AT activity had 84.1% sensitivity and
100% specificity, with an AUC of 0.94 (Fig. 2d). These
findings suggest that the plasma A1AT activity is a better
biomarker than plasma A1AT protein for the early detec-
tion of CRC. Recent studies indicate that certain mutations
in SERPINA1 gene result in A1AT proteins with an im-
paired anti-protease activity [33, 34]. These variants which
are secreted at normal or enhanced levels but lack anti-
protease activity, are likely over-estimate the amount of
functional A1AT measured in the circulation. Therefore,
the measurement of the A1AT activity may be a better
biomarker than A1AT protein level.
Our results are also in agreement with previous studies of
the proteomic analysis of serum samples reporting that
A1AT outperforms serum CEA for discriminating CRC pa-
tients from healthy individuals [25, 35]. However, elevated
blood A1AT levels are observed in other types of malignant
and non-malignant diseases. Therefore, its measurement
alone does not provide the required specificity for the early
detection of CRC.
We also analyzed the cases for the presence of A1AT-
deficient S and Z alleles. We did not detect any S or Z variants
in any of 113 CRC samples studied. These results demonstrat-
ed that 100% of CRC patients had normal MM genotype. In a
study of 267 CRC patients from Spain, Pérez-Holanda et al.
[22] observed a higher frequency of A1AT deficient-
associated Z allele in CRC cases than healthy controls.
However, they found no significant difference in serum
A1AT concentrations between normal (MM) and deficient
(MS, MZ or SZ) genotypes.
Previous immunohistochemical studies of biopsies from
gastric and CRC tumors indicated a local overexpression of
A1AT by tumor cells and a higher expression of A1AT in
advanced adenocarcinomas than in early carcinomas [36,
37]. It has been reported that A1AT expression in cells is
controlled by promoter DNA methylation [30]. Therefore,
we examined the methylation status of SERPINA1 gene pro-
moter in 86 tumors and their adjacent normal tissues.
SerpinA1 promoter was either fully-methylated or hemi-
methylated in tumor tissues (Table 3). The rate of fully-
methylated gene in normal tissues was significantly higher
than that in tumor tissues (53.2% versus 8.1%, p < 0.0001).
The results also indicated that SERPINA1 was more fre-
quently methylated in well-differentiated tumors (p < 0.05)
than in other differentiation subgroups. There was no rela-
tionship between gene promoter methylation and other clin-
icopathological features.
Multiple mechanisms have been proposed to explain the
elevated levels of serum AIAT in cancer patients, including an
enhanced A1AT production by mononuclear cells, liver or
tumor cells themselves [11, 37, 38]. Since transcriptionally
active A1AT gene is hypomethylated and the inactive gene
is hypermethylated [30], it is plausible that tumors with the
hypomethylated promoter express more A1AT protein than
normal tissues and tumors with the hypermethylated promot-
er. Our findings suggest that A1AT production by tumor cells
themselves might have a role for the elevation of plasma
A1AT levels in CRC patients. This viewpoint is supported
by our observation of higher levels of plasma A1AT in cases
with large tumor size (≥5 cm) than in those with small tumors
(<5 cm) (p < 0.0001) (Table 2). Yet more in-depth studies
using larger sample sizes are necessary to validate the findings
of present study.
Table 3 SERPINA1 gene promoter methylation and clinicopathological
features of CRC patients
Variables N (%) M
N (%)
M/U
N (%)
p
Total 86 7 (8.1) 79 (91.9)
Age
<60 30 (34.9) 2 (28.6) 34 (43) 0.69a
>60 50 (58.1) 5 (71.4) 45 (57)
Sex
Female 30 (34.9) 2 (28.6) 28 (35.4) 1.00a
Male 56 (65.1) 5 (71.4) 51 (64.6)
Clinical stage
I 12 (14) 0 (0) 12 (15.2) 0.65b
II 50 (58.1) 5 (71.4) 45 (57)
III 21 (24.4) 2 (28.6) 19 (24.1)
IV 3 (3.5) 0 (0) 3 (3.8)
Differentiation grade
Poor 5 (5.8) 1 (14.3) 4 (5.1) 0.029b
Moderate 41 (47.7) 0 (0) 41 (51.9)
Well 40 (46.5) 6 (85.7) 34 (43)
Tumor site
Right side 10 (11.6) 0 (0) 22 (27.8) 1.00a
Left side 76 (88.4) 7 (100) 57 (72.2)
M Methylated promoter, M/U Hemi-methylated promoter
aP-value from Fisher’s exact tests
bP-value from Chi-Square tests
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Conclusion
Our study indicated that A1AT concentrations and activity
levels in circulation have a better sensitivity and specificity
than CEA measurement for the early detection of CRC. Our
findings also suggest that the increased expression of A1AT
gene in primary tumor tissues because of the promoter hypo-
methylation might play a role in increasing plasma A1AT
levels in CRC patients.
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